KPG-121, a novel cereblon modulator, in patients with metastatic castration resistant prostate cancer: Results of a phase I multiple ascending dose study. Baseline PSMA PET/CT as a predictive ...
CIRT leads to temporary urinary function decline, normalizing within three months and stable for five years. Prostate volume decreases significantly without ADT, remaining reduced for five years. T ...
Dr Hannah McManus looks ahead to the release of new data from phase 3 clinical trials that will inform multidisciplinary ...
One of the most common concerns about treating prostate cancer is preserving sexual function and urinary control. For some prostate cancers, newer treatments offering an alternative to radiation and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results